 Home > Active Ingredient News > Drugs Articles > September biomedical industry operation report: the amount of financing fell by more than half, and more than 120,000 new enterprises were added

September biomedical industry operation report: the amount of financing fell by more than half, and more than 120,000 new enterprises were added

 Last Update: 2022-10-20
 Source: Internet
 Author: User

Tags

ln 0 1

hla class 1

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

01 Enterprise situation analysis

As of the end of September 2022, a total of 1019937 biomedical enterprises have been established in China in 2022; Among them, 124362 new enterprises were added in September, an increase of 4.
10%
over the previous month.

Among them, 124362 new enterprises were added in September, an increase of 4.
10%
over the previous month.

From the perspective of the geographical distribution of new enterprises, the top ten provinces in the number of enterprises are Guangdong Province, Shandong Province, Henan Province, Beijing Municipality, Hunan Province, Shanghai Municipality, Jiangsu Province, Anhui Province, Yunnan Province and Zhejiang Province, accounting for 60.
31%
of the total number of new enterprises in the country.
The top ten cities in terms of the number of enterprises are Beijing, Shanghai, Guangzhou, Shenzhen, Zhengzhou, Changsha, Hangzhou, Wuhan, Chongqing and Chengdu, accounting for 26.
92%
of the total number of new enterprises in the country.

Table 1: Top 10 provinces and cities with new companies added in September

Source: Firestone Creation Industry Data Center

02 Analysis of industrial financing

In September 2022, a total of 79 financing events occurred in the biomedical field across the country, with a cumulative amount of 4.
602 billion yuan, compared with the previous month, the number of financing events decreased by 22.
55%, and the amount of financing decreased by 52.
63%.

A total of 79 financing events occurred in the field of biomedicine nationwide, with a cumulative amount of 4.
602 billion yuan, compared with the previous month, the number of financing events decreased by 22.
55%, and the amount of financing decreased by 52.
63%.

In terms of the number of financings, Series A and Angel rounds had the most financing events, with 18 and 14 respectively
.
In terms of financing amount, Series A financing obtained the highest financing amount of 1.
324 billion yuan; secondly, Series B financing amount is also more prominent, with a financing amount of 869 million yuan
.

Table 2: Distribution of medical and health financing events in September

Source: Firestone Creation Industry Data Center

From the perspective of financing regions, this month's financing events were mainly distributed in Shanghai (19 cases) and Jiangsu Province (16 cases).

In terms of financing amount, Shanghai is the most prominent, with a financing amount of 1.
733 billion yuan; secondly, Jiangsu Province is also more prominent, with a financing amount of 939 million yuan
.

In terms of financing amount, Shanghai is the most prominent, with a financing amount of 1.
733 billion yuan; secondly, Jiangsu Province is also more prominent, with a financing amount of 939 million yuan
.

Table 3: Regional distribution of financing events in September

Source: Firestone Creation Industry Data Center

From the perspective of financing amount, there were 79 financing events this month, of which 26 were financing events with a single financing amount of more than 100 million yuan, with a total financing amount of about 3.
885 billion yuan, accounting for 84.
41%
of the total financing scale this month.

Figure 1: Distribution of financing amounts in September Source: Firestone Creation Industry Data Center

03 Analysis of listed enterprises

As of the end of September 2022, there were 1,357 listed biopharmaceutical companies in China, and 14 new listed biopharmaceutical companies were added
in September.
The market distribution is 4 listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange, 1 listed on the Growth Enterprise Market of the Shenzhen Stock Exchange, 5 listed on the New Third Board, 2 listed on the Old Third Board, and 2 listed on the main board of the Hong Kong Stock Exchange
.
The total market value of listed biomedical enterprises in China reached 10.
58 trillion yuan
.
Among them, there are 12 listed biomedical companies with a market value of more than 100 billion yuan, distributed in innovative drugs, medical devices, medical services and other fields
.

In September,
14 new listed biopharmaceutical companies were listed.

Table 4: Top 10 biopharmaceutical companies by market capitalization in September

Source: Firestone Creation Industry Data Center

Table 5: List of biopharmaceutical listed companies in September

Source: Firestone Creation Industry Data Center

Compared with the previous month, Wenzheng Technology, Ruilkang, Beisheng Pharmaceutical, Aiji Aimu, and Gute Ultrasound increased significantly, and the market value of Chinese Zheng Technology (831556) increased by 269.
21%, and the market value of Ruilkang (839881) increased by 265.
45%; ST Heath, Sinopharm Technology Co.
, Ltd.
, Keju Biotechnology, Sheng Qi'an and Rongen Group fell significantly, of which the market value of ST Heath (871107) fell by 93.
72%, and the market value of Sinopharm Technology (08156) fell by 59.
55%.

Table 6: Top 5 biopharmaceutical companies in September

Source: Firestone Creation Industry Data Center

04 Analysis of drug clinical trials

In September 2022, a total of 322 products were approved for clinical trials across the country, an increase of 28.
3%
compared with the previous month.
Among them, there are 100 in the field of biological medicine, 5 in the field of traditional Chinese medicine, and 217 in the field of chemical medicine
.

From the perspective of clinical trial companies, clinical trials approved this month came from 146 companies, of which Eli Lilly was the most approved, with 9 clinical approvals
.

From the perspective of clinical trial stage, there are 74 phase I.
clinical trials, 42 phase II clinical trials, 24 phase III clinical trials, and 5 phase IV clinical trials
.

Table 7: New phase III clinical trials were conducted in September

Source: Firestone Creation Industry Data Center

05 Analysis of drug approval

In September 2022, a total of 55 products were approved for marketing across the country, a decrease of 12.
7%
compared with the previous month.
It produces 52 drugs in China and imports 3 drugs
.
From the perspective of drug types, there are 0 in the field of biological medicine, 2 in the field of traditional Chinese medicine, and 53 in the field of chemical medicine
.

This month, the State Medical Products Administration approved a total of 3 new drugs on the market, including 2 Class 1 new drugs
.

Table 8: New drugs approved for marketing by the State Medical Products Administration in September

Source: Firestone Creation Industry Data Center

This month, seven medicines were included in the priority review process
by CDE.

Table 9: Varieties approved by the CDE for priority review in September

Source: Firestone Creation Industry Data Center

06 Analysis of medical device approval

In September 2022, a total of 2,771 medical devices were approved for the first time in China, including 2,616 Chinese-made devices and 155 imported devices
.
From the perspective of product registration classification, there are 187 Class III medical devices, 991 Class II medical devices, and 1593 Class I medical devices
.

From the perspective of the geographical distribution of approved products, the top ten provinces approved for the three types of devices are Jiangsu Province, Guangdong Province, Beijing Municipality, Shanghai City, Shandong Province, Zhejiang Province, Tianjin City, Henan Province, Hunan Province and Fujian Province, accounting for 80.
87%
of the total number of new 3 types of device products in the country.
The top ten cities approved for the three types of devices are Shenzhen, Beijing, Shanghai, Suzhou, Wuxi, Tianjin, Nanjing, Changzhou, Guangzhou and Weihai, accounting for 57.
38%
of the total number of new three types of equipment products in the country.

Table 10: Top 10 provinces and cities approved for medical devices for the first time in September

Source: Firestone Creation Industry Data Center

In September 2022, a total of 7 products entered the priority approval channel and a total of 12 products entered the special review and approval channel
.

Table 11: Products approved for priority and special approval in September

Source: Firestone Creation Industry Data Center

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.